SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike is facing a massive sell-off as a weak revenue outlook and significant declines in the China market overshadow an earnings beat, fueling intense debate over whether this decade-long low represents a generational buying opportunity or a deeper structural decline. The community is sharply divided, with many traders betting on a sharp V-shaped recovery and a "juicy" dividend, while skeptics argue that the brand's long-term growth is dead and are cautioning against catching a falling knife.

RH operates as a holding company which operates the business through its subsidiary Restoration Hardware, Inc. It offers furniture, lighting, textiles, bath ware, decor, outdoor and garden, as well as baby and child products. The company operates an integrated business with multiple channels of distribution including galleries, source books and websites. The company was founded by Stephen J. Gordon in 1980 and is headquartered in Corte Madera, CA.

RH - Ordinary Shares - Class A

Restoration Hardware

Restoration Hardware is trending due to significant volatility following a quarterly earnings report that featured a revenue beat but a notable miss on earnings expectations, coupled with cautious guidance linked to ongoing tariff pressures and housing market headwinds. Investors are actively debating the stock's future, weighing concerns over debt and luxury spending against potential upside from long-term global expansion and anticipation of favorable legal outcomes regarding trade tariffs.

D-Wave Quantum, Inc. engages in the development and delivery of quantum computing systems, software, and services. It provides customers with access to the company’s quantum computing systems via the cloud in the form of quantum computing as a service. It offers professional services such as customer assistance in identifying and implementing quantum-computing applications. The company was founded on January 25, 2022 and is headquartered in Palo Alto, CA.

D-Wave Quantum Inc

D-Wave Quantum is facing significant volatility as investors weigh the company's long-term potential in quantum annealing against broader market fears, recession risks, and aggressive competitive pressure from IBM's recent advancements. While bulls highlight D-Wave's dual-platform strategy, growing bookings, and strategic government partnerships, the community remains divided, with skeptics pointing to high dilution, lack of profitability, and the stock's recent steep correction as signs of a struggling speculative play.

United States Antimony Corp. engages in the extraction, processing and sale of antimony, zeolite, silver, and gold products. It operates through the following segments: United States Antimony Operations, Mexican Antimony Operations, Precious Metals Recovery, and United States Zeolite Operations. The company was founded by John C. Lawrence in June 1968 and is headquartered in Dallas, TX.

United States Antimony Corp.

United States Antimony Corp. is trending as the community closely monitors the company's progress on scaling its proprietary hydrometallurgical facility in Bolivia and its upcoming implementation in Idaho. Investors are actively discussing the potential impact of this technology on processing critical minerals, alongside speculation regarding anticipated Department of Defense shipments and the broader strategic necessity of domestic supply chains for antimony and tungsten.

Wingstop, Inc. is a franchisor and chicken wings-focused restaurant. The firm is engaged in the flavor business offering cooked-to-order, hand-sauced, and tossed classic and boneless wings, tenders and chicken sandwiches in flavors, with signature sides, such as its seasoned fries and house made ranch and bleu cheese dips. The company was founded in 1994 and is headquartered in Dallas, TX.

Wingstop Inc

Wingstop is facing significant selling pressure as investors grapple with shifting consumer sentiment and broader market volatility, with community discussions split between long-term growth optimism and concerns regarding current valuation levels. The stock is currently under a microscope as market participants debate whether these lows present a buying opportunity or a warning sign of further downward consolidation.

Regencell Bioscience Holdings Ltd. is a early-stage bioscience company that focuses on research, development and commercialization of Traditional Chinese Medicine for the treatment of neurocognitive disorders and degeneration, specifically Attention Deficit Hyperactivity Disorder and Autism Spectrum Disorder. The company was founded by Yat-Gai Au on October 30, 2014 and is headquartered in Hong Kong.

Regencell Bioscience Holdings Ltd

Regencell Bioscience is experiencing intense volatility and social media attention as traders monitor its low-float structure and history of sharp, squeeze-driven price moves. The community is actively debating whether current price action signals a repeat of past parabolic runs, with many focusing on the high cost to borrow, limited share availability, and the potential for a swift short squeeze.

SharonAI Holdings, Inc. engages in providing high-performance computing (HPC), artificial intelligence (AI), and cloud GPU compute infrastructure technologies. The company was founded on December 30, 2024 and is headquartered in New York, NY.

SharonAI Holdings Inc. - Ordinary Shares - Class A

SharonAI is trending following the announcement of a massive multi-year AI infrastructure contract, with the community actively speculating that its low float could trigger a significant short squeeze. Traders are closely monitoring the stock's price action and volume levels for signs of a parabolic move, while debating whether the current market valuation fully reflects the scale of the new partnership.

Oric Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the development of cancer treatments that address mechanisms of therapeutic resistance. It specializes in hormone-dependent cancers, key tumor dependencies, and precision oncology. The company was founded by Charles L. Sawyers, Richard A. Heyman, and Scott Lowe in 2014 and is headquartered in South San Francisco, CA.

ORIC Pharmaceuticals Inc

ORIC Pharmaceuticals is trending following an update from its Phase 1b trial of rinzimetostat in combination with darolutamide for prostate cancer, which triggered a significant stock pullback amid investor scrutiny over safety profiles at higher doses. The community is actively debating whether the selloff is an overreaction to trial data, with many bulls highlighting the company's strong cash position and clinical potential versus skeptics pointing to broader sector safety concerns.

SPDR S&P 500 ETF TRUST - Units of undivided interest in SPDR Trust Series 1

The S&P 500 is experiencing heightened volatility as market participants weigh conflicting reports regarding geopolitical tensions in the Middle East and anticipated commentary from political leadership. Investors are actively debating whether recent gains represent a durable recovery or a bull trap, with many closely monitoring crude oil fluctuations and potential impacts on global trade as they hedge against significant uncertainty ahead of scheduled policy speeches.

Mega Fortune Co., Ltd. operates as a holding company which provides information technology services. It specializes in delivering comprehensive IoT solutions and services across various industries. The firm offers low carbon property management, energy, stock and GreenTech management services. The company was founded in 2011 and is headquartered in Hong Kong.

Mega Fortune Co Ltd.

Mega Fortune Company Limited

Mega Fortune Company Limited is generating significant buzz as a low-float Chinese IPO that traders are closely monitoring for potential high-volatility price swings. Community discussions are split between those betting on aggressive momentum rallies similar to past sector runs and skeptics warning of a pump-and-dump cycle.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

NRx Pharmaceuticals' (NRXP) Buy Rating Reaffirmed at D. Boral Capital

D. Boral Capital reiterated a "buy" rating and issued a $34.00 price objective on shares of NRx Pharmaceuticals in a research report on Tuesday...

NRx Pharmaceuticals (NASDAQ:NRXP) Receives "Buy" Rating from BTIG Research

BTIG Research reaffirmed a "buy" rating and set a $25.00 target price on shares of NRx Pharmaceuticals in a research note on Tuesday...

NRx Pharmaceuticals (NASDAQ:NRXP) Releases Earnings Results, Beats Expectations By $0.28 EPS

NRx Pharmaceuticals (NASDAQ:NRXP - Get Free Report) posted its earnings results on Monday. The company reported $0.19 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.09) by $0.28...

NRx Pharmaceuticals Q4 Earnings Call Highlights

NRx Pharmaceuticals (NASDAQ:NRXP) executives used the company's fourth-quarter 2025 results call to outline what they described as a "pivotal and transformative" year, highlighting advancing regulatory pathways for preservative-free ketamine and an investigational ketamine product, as well as an exp...

NRx Pharmaceuticals Wraps Virtual Annual Meeting, Eyes Pivotal 2025 Earnings Call Ahead

NRx Pharmaceuticals (NASDAQ:NRXP) held its 2025 annual meeting of stockholders in a virtual format, with Chairman Jonathan Javitt calling the meeting to order at 10:00 a.m. Eastern. Javitt said the company hopes to hold future meetings in person "now that we have clinical facilities open," adding th...

NRx Pharmaceuticals, Inc. (NRXP) Surpasses Q4 Earnings Estimates

NRx Pharmaceuticals (NRXP) delivered earnings and revenue surprises of +323.53% and -84.40%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

NRx Pharmaceuticals' (NRXP) "Buy" Rating Reaffirmed at D. Boral Capital

D. Boral Capital reiterated a "buy" rating and set a $34.00 price target on shares of NRx Pharmaceuticals in a report on Monday...

NRx Pharma Stock Jumps After FDA Signals Path To NDA For Ketamine Depression Drug

The FDA signals its willingness to review NRx Pharmaceuticals' NRX-100 NDA, boosting optimism around its depression treatment.read more...

D. Boral Capital Reaffirms "Buy" Rating for NRx Pharmaceuticals (NASDAQ:NRXP)

D. Boral Capital restated a "buy" rating and set a $34.00 price target on shares of NRx Pharmaceuticals in a report on Monday...

NRx Pharmaceuticals (NRXP) to Release Earnings on Friday

NRx Pharmaceuticals (NASDAQ:NRXP) will be releasing its Q4 2025 earnings before the market opens on Friday, March 13. (View Earnings Report at...

NRX Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in developing novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company was founded by Jonathan C. Javitt on September 18, 2017 and is headquartered in Wilmington, DE.

NRX Pharmaceuticals Inc

Thematic ETFs

Prediction Markets

OpenClaw & Agentic-Directed Trading

Tokenization

Recognizing the tool or mechanism that redefined how we trade. From prediction markets to next-gen tech, this award honors the innovation that pushed the boundaries of access and efficiency in modern finance.

NRXP
NRX Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest NRXP News

NRXPNRX Pharmaceuticals Inc